|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association of k-ras, b-raf,and p53 status with the treatment effect of bevacizumab 显示文摘 | Ince WL Jubb AM Holden SN | 2005 | J NatlCancer Inst2005，97，13： | 1 |
| 2 | Clinical e- valuation of ZD647g, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors 显示文摘 | HOLDEN SN ECKHARDT SG BASSER R | 2005 | Ann Oncol2005，16，8： | 1 |
| 3 | A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors显示文摘 | Basche M Gustafson DL Holden SN | 2006 | Clin Cancer Res2006，12，18： | 1 |
| 4 | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGFreceptor signaling, in patients with solid, malignant tumors 显示文摘 | Holden SN Eckhardt SG Basser R el al | 2005 | Ann Oncol2005，16，： | 1 |
| 5 | Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC)显示文摘 | Holden SN Ryan E | 2005 | J Clin Oncol2005，23，16： | 1 |
| 6 | Clinical evaluation of ZD6474,anorally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors显示文摘 | Holden SN Eckhardt SG Basser R | 2005 | Ann On col2005，16，8： | 1 |
| 7 | Functional analysis of luxS in Staphylococcus aureus reveals a role in metabolism but not quorum sensing显示文摘 | Doherty N Holden MT Qazi SN | 2006 | J Bacteriol2006，188，8： | 1 |
| 8 | Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab 显示文摘 | Ince WL Jubb AM Holden SN | 2005 | J Natl Cancer Inst2005，97，： | 1 |
| 9 | Association of k - ras, b - raf and p53 status with the treatment effect ofbevacizumab 显示文摘 | Ince WL Jubb AM Holden SN | 2005 | J Natl Cancer Inst2005，97，13： | 1 |
| 10 | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab显示文摘 | Scappaticci FA Skillings JR Holden SN | 2007 | J Natl Cancer Inst2007，99，： | 1 |
| 11 | A phase I biological and pharmacologic study of the heparanase in- hibitor PI-88 in patients with advanced solid tumors显示文摘 | Basche M Gustafson DL Holden SN | 2006 | Clin Cancer Res2006，12，18： | 1 |
| 12 | A phase I biological and pharmacologic study of the heparanase inhibitor PI- 88 in patients with advanced solid tumors显示文摘 | BASCHE M GUSTAFSON DL HOLDEN SN | 2006 | Clin Cancer Res2006，12，18： | 1 |
| 13 | A phase 1 biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors显示文摘 | Gustafsen DL Holden SN | 2006 | Clin Cancer Res2006，12，18： | 1 |
| 14 | A phase Ⅰ biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors显示文摘 | Basche M Gustafson DL Holden SN | 2006 | Clin Cancer Res2006，12，18： | 1 |
| 15 | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors显示文摘 | HURWITZ H HOLDEN SN ECKHARDT SG | 2002 | Proc Am Soc Clin Oncol2002，21，82： | 1 |
| 16 | Arterial thrombo- embolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab 显示文摘 | Scappaticci FA Ski|lings JR Holden SN | 2007 | J Natl Cancer Inst2007，99，16： | 1 |
| 17 | Arterial thromboebolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab 显示文摘 | Scappaticci FA Skillings JR Holden SN | 2008 | J Natl Cancer Inst2008，100，2： | 1 |
| 18 | Arterial thrombo- embolic events in patients with metastatic careinoma treated with chemotherapy and bevacizumab 显示文摘 | Scappaticci FA Skillings JR Holden SN | 2007 | J Natl Cancer lnst2007，99，16： | 1 |
| 19 | Arterial throm- boembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab 显示文摘 | Scappaticci FA Skillings JR Holden SN | 2007 | J Natl Cancer Inst2007，99，16： | 1 |
| 20 | Arterial thromboembolie events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab 显示文摘 | SCAPPATICCI F A SKILLINGS J R HOLDEN SN | 2007 | J Natl Cancer Inst2007，99，16： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员